公开(公告)号：US20240247312A1

公开(公告)日：2024-07-25

申请号：US18014801

申请日：2021-07-05

申请人： BIOMÉRIEUX ,  BIOASTER

发明人： Laurence VACHOT ,  François MALLET ,  Guillaume MONNERET ,  Virginie MOUCADEL ,  Alexandre PACHOT ,  Estelle PERONNET ,  Thomas RIMMELÉ ,  Julien TEXTORIS ,  Fabienne VENET

IPC分类号： C12Q1/6883 ,  C12Q1/6851

CPC分类号： C12Q1/6883 ,  C12Q1/6851 ,  C12Q2600/118 ,  C12Q2600/158

摘要： An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection in a patient, including a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor located on chromosome 2 in the region 2q11-2q12, in a biological sample from the patient.

公开(公告)号：US20240247275A1

公开(公告)日：2024-07-25

申请号：US18416643

申请日：2024-01-18

申请人： The Trustees of Columbia University in the City of New York

发明人： Antonio IAVARONE ,  Anna LASORELLA ,  Raul RABADAN

IPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/28 ,  C12N9/12 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： C12N15/62 ,  C07K14/47 ,  C07K14/71 ,  C07K14/82 ,  C07K16/18 ,  C07K16/2863 ,  C12N9/12 ,  C12Q1/6886 ,  G01N33/57492 ,  C07K2319/00 ,  C07K2319/73 ,  C12Q2600/158 ,  G01N2333/91205

摘要： The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

公开(公告)号：US12043870B2

公开(公告)日：2024-07-23

申请号：US16753039

申请日：2018-10-02

申请人： The Broad Institute, Inc. ,  Massachusetts Institute of Technology ,  Dana-Farber Cancer Institute, Inc.

发明人： Aviv Regev ,  Orit Rozenblatt-Rosen ,  Benjamin Izar ,  Livnat Jerby ,  Asaf Rotem

IPC分类号： C12Q1/6886 ,  A61K31/506 ,  A61K39/395

CPC分类号： C12Q1/6886 ,  A61K31/506 ,  A61K39/3955 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically. Specifically, disclosed is a resistance program identified by a comprehensive single-cell profiling study in melanoma patients, which was validated in two large validation cohorts. Using a large-scale in silico prediction, CDK4/6 inhibitors were identified as a class of drugs that may reverse this resistance program. These predictions were validated in melanoma cell lines, patient-derived co-culture models, and melanoma in vivo models, which show that the combination of abemaciclib and immune checkpoint blockade (ICB) overcome intrinsic drug resistance. The present invention provides for detecting an immunotherapy resistance signature and modulating the signature with CDK4/6 inhibition. Also provided is a novel phased immunotherapy and CDK4/6 inhibitor combination therapy regimen.

公开(公告)号：US20240240255A1

公开(公告)日：2024-07-18

申请号：US18021748

申请日：2021-08-17

申请人： BicycleTx Limited

发明人： Stephen J. BLAKEMORE ,  Tara GELB ,  Sean M. SANTOS ,  Heather B. COHEN

IPC分类号： C12Q1/6886 ,  A61K39/00 ,  A61K47/64 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  A61K47/6415 ,  G01N33/57407 ,  A61K2039/505 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/52

摘要： The present invention relates to a Bicycle toxin conjugate or a Bicycle tumor targeted immune agonist specific for Nectin-4, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

公开(公告)号：US20240240253A1

公开(公告)日：2024-07-18

申请号：US18289605

申请日：2022-05-05

申请人： SAPERE BIO, INC.

发明人： Natalia MITIN

IPC分类号： C12Q1/6883 ,  C12Q1/6851

CPC分类号： C12Q1/6883 ,  C12Q1/6851 ,  C12Q2600/106 ,  C12Q2600/158

摘要： The disclosure relates to methods, kits and systems for modulating and predicting changes in p16 and organismal cellular senescence.

公开(公告)号：US20240240247A1

公开(公告)日：2024-07-18

申请号：US18538986

申请日：2023-12-13

申请人： GUARDANT HEALTH, INC.

发明人： AmirAli TALASAZ ,  Helmy ELTOUKHY ,  Stefanie Ann Ward MORTIMER

IPC分类号： C12Q1/6869 ,  C12Q1/6886 ,  G16B15/00

CPC分类号： C12Q1/6869 ,  C12Q1/6886 ,  C12Q2535/122 ,  C12Q2600/158 ,  G16B15/00

摘要： Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.

公开(公告)号：US12037646B2

公开(公告)日：2024-07-16

申请号：US16778237

申请日：2020-01-31

申请人： INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

发明人： Gu Kong ,  Jeong Yeon Lee ,  Hee-Joo Choi ,  Ha Ni Jo

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158

摘要： A function of cyclin-dependent kinase 12 (CDK12) as a biomarker for a human epidermal growth factor receptor 2 (HER2)-positive cancer and anti-HER2 therapy, and a use of the CDK12 are provided. The CDK12 may be used for companion diagnostics of a HER2-targeted therapeutic agent for a subject having HER2+ cancer as a prognostic factor and a predictive factor for response of the subject to the anti-HER2-targeted therapeutic agent in HER2+ cancer, or used to check the probability of expressing resistance to the HER2-targeted therapeutic agent. When the CDK12 is amplified or expressed at a level higher than a reference value, the CDK12 may be suppressed to overcome the resistance to the HER2 therapeutic agent and improve a therapeutic effect, thereby improving the therapeutic efficiency of HER2-positive cancer.

公开(公告)号：US20240218468A1

公开(公告)日：2024-07-04

申请号：US18557784

申请日：2022-05-11

申请人： Inflammatix, Inc.

发明人： Timothy Elisha Sweeney ,  Yudong He ,  Rushika Pandya

IPC分类号： C12Q1/70

CPC分类号： C12Q1/701 ,  C12Q2600/106 ,  C12Q2600/158

摘要： Systems, methods, compositions, apparatuses, and kits for determining the viral infection status of subjects using respiratory samples, and for determining effective triage strategies for such subjects, are provided herein. The disclosed methods and compositions involve biomarkers identified from the application of a machine learning workflow to viral training data from respiratory samples. The biomarkers allow the calculation of a score that can be used to determine the viral infection status of the subjects.

公开(公告)号：US20240218454A1

公开(公告)日：2024-07-04

申请号：US18556748

申请日：2022-04-22

申请人： H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

发明人： Eric B. HAURA ,  John M. KOOMEN ,  Theresa A. BOYLE ,  Sudhir PUTTY REDDY ,  Aileen Y. ALONTAGA

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

摘要： Clinical testing to identify targeted therapies is frequently performed with next generation sequencing (NGS). Clinical action and trial enrollment is often based on expected associations of gene changes with protein expression or action. However, comprehensive RNA and protein expression is not routinely performed in the clinical repertoire of testing clinical tumor samples. The relationship between genetic changes, including gene amplification, with increased RNA and protein expression in the context of clinical testing remains poorly understood. What are needed are new methods of identifying targets that account for both genomic and proteomic information. Disclosed are novel RNA and protein expression panels and methods of using said panels for the detection of cancer and determining the suitability of a subject for a treatment regimen or clinical trial.

公开(公告)号：US20240218450A1

公开(公告)日：2024-07-04

申请号：US18338974

申请日：2023-06-21

申请人： Board of Regents, The University of Texas System ,  Yale University

发明人： William fraser SYMMANS ,  Bruno SINN ,  Christos HATZIS ,  Chunxiao FU ,  Rosanna LAU

IPC分类号： C12Q1/6886 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/566 ,  A61K45/06 ,  A61P35/04 ,  G16B10/00 ,  G16B25/10 ,  G16B25/20

CPC分类号： C12Q1/6886 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/566 ,  A61K45/06 ,  A61P35/04 ,  G16B10/00 ,  G16B25/10 ,  G16B25/20 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

摘要： Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.